Choroidal Neovascularization Drug Market, Global Outlook and Forecast 2022-2028

Choroidal Neovascularization Drug Market, Global Outlook and Forecast 2022-2028

Report Code: KNJ1281648 | No. of Pages: 116 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Apr-2022
This report contains market size and forecasts of Choroidal Neovascularization Drug in global, including the following market information:
Global Choroidal Neovascularization Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Choroidal Neovascularization Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Choroidal Neovascularization Drug companies in 2021 (%)
The global Choroidal Neovascularization Drug market was valued at  million in 2021 and is projected to reach US$  million by 2028, at a CAGR of  % during the forecast period.
The U.S. Market is Estimated at $  Million in 2021, While China is Forecast to Reach $  Million by 2028.
AVMOC-001 Segment to Reach $  Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Choroidal Neovascularization Drug include Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Cleveland BioLabs, Inc., Cumberland Pharmaceuticals, Inc., Diffusion Pharmaceuticals Inc., Eli Lilly and Company, GNI Group Ltd., Humanetics Corporation and INSYS Therapeutics, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Choroidal Neovascularization Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Choroidal Neovascularization Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Choroidal Neovascularization Drug Market Segment Percentages, by Type, 2021 (%)
    AVMOC-001
    BB-3
    BBT-007
    DG-3
    Entolimod
    EWA-001
    Others
Global Choroidal Neovascularization Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Choroidal Neovascularization Drug Market Segment Percentages, by Application, 2021 (%)
    Clinic
    Hospital
    Others
Global Choroidal Neovascularization Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Choroidal Neovascularization Drug Market Segment Percentages, By Region and Country, 2021 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Choroidal Neovascularization Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Choroidal Neovascularization Drug revenues share in global market, 2021 (%)
Key companies Choroidal Neovascularization Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Choroidal Neovascularization Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Cellphire, Inc.
    Chrysalis BioTherapeutics, Inc.
    Cleveland BioLabs, Inc.
    Cumberland Pharmaceuticals, Inc.
    Diffusion Pharmaceuticals Inc.
    Eli Lilly and Company
    GNI Group Ltd.
    Humanetics Corporation
    INSYS Therapeutics, Inc.
    Meabco A/S
    Neumedicines Inc.
    Onconova Therapeutics, Inc.
    PharmaIN Corporation
    Pluristem Therapeutics Inc.
    ProCertus BioPharm Inc.
    RDD Pharma Ltd.
    RedHill Biopharma Ltd.
    RxBio, Inc.
    Soligenix, Inc.
1 Introduction to Research & Analysis Reports
    1.1 Choroidal Neovascularization Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Choroidal Neovascularization Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Choroidal Neovascularization Drug Overall Market Size
    2.1 Global Choroidal Neovascularization Drug Market Size: 2021 VS 2028
    2.2 Global Choroidal Neovascularization Drug Revenue, Prospects & Forecasts: 2017-2028
    2.3 Global Choroidal Neovascularization Drug Sales: 2017-2028
3 Company Landscape
    3.1 Top Choroidal Neovascularization Drug Players in Global Market
    3.2 Top Global Choroidal Neovascularization Drug Companies Ranked by Revenue
    3.3 Global Choroidal Neovascularization Drug Revenue by Companies
    3.4 Global Choroidal Neovascularization Drug Sales by Companies
    3.5 Global Choroidal Neovascularization Drug Price by Manufacturer (2017-2022)
    3.6 Top 3 and Top 5 Choroidal Neovascularization Drug Companies in Global Market, by Revenue in 2021
    3.7 Global Manufacturers Choroidal Neovascularization Drug Product Type
    3.8 Tier 1, Tier 2 and Tier 3 Choroidal Neovascularization Drug Players in Global Market
        3.8.1 List of Global Tier 1 Choroidal Neovascularization Drug Companies
        3.8.2 List of Global Tier 2 and Tier 3 Choroidal Neovascularization Drug Companies
4 Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Choroidal Neovascularization Drug Market Size Markets, 2021 & 2028
        4.1.2 AVMOC-001
        4.1.3 BB-3
        4.1.4 BBT-007
        4.1.5 DG-3
        4.1.6 Entolimod
        4.1.7 EWA-001
        4.1.8 Others
    4.2 By Type - Global Choroidal Neovascularization Drug Revenue & Forecasts
        4.2.1 By Type - Global Choroidal Neovascularization Drug Revenue, 2017-2022
        4.2.2 By Type - Global Choroidal Neovascularization Drug Revenue, 2023-2028
        4.2.3 By Type - Global Choroidal Neovascularization Drug Revenue Market Share, 2017-2028
    4.3 By Type - Global Choroidal Neovascularization Drug Sales & Forecasts
        4.3.1 By Type - Global Choroidal Neovascularization Drug Sales, 2017-2022
        4.3.2 By Type - Global Choroidal Neovascularization Drug Sales, 2023-2028
        4.3.3 By Type - Global Choroidal Neovascularization Drug Sales Market Share, 2017-2028
    4.4 By Type - Global Choroidal Neovascularization Drug Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
    5.1 Overview
        5.1.1 By Application - Global Choroidal Neovascularization Drug Market Size, 2021 & 2028
        5.1.2 Clinic
        5.1.3 Hospital
        5.1.4 Others
    5.2 By Application - Global Choroidal Neovascularization Drug Revenue & Forecasts
        5.2.1 By Application - Global Choroidal Neovascularization Drug Revenue, 2017-2022
        5.2.2 By Application - Global Choroidal Neovascularization Drug Revenue, 2023-2028
        5.2.3 By Application - Global Choroidal Neovascularization Drug Revenue Market Share, 2017-2028
    5.3 By Application - Global Choroidal Neovascularization Drug Sales & Forecasts
        5.3.1 By Application - Global Choroidal Neovascularization Drug Sales, 2017-2022
        5.3.2 By Application - Global Choroidal Neovascularization Drug Sales, 2023-2028
        5.3.3 By Application - Global Choroidal Neovascularization Drug Sales Market Share, 2017-2028
    5.4 By Application - Global Choroidal Neovascularization Drug Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
    6.1 By Region - Global Choroidal Neovascularization Drug Market Size, 2021 & 2028
    6.2 By Region - Global Choroidal Neovascularization Drug Revenue & Forecasts
        6.2.1 By Region - Global Choroidal Neovascularization Drug Revenue, 2017-2022
        6.2.2 By Region - Global Choroidal Neovascularization Drug Revenue, 2023-2028
        6.2.3 By Region - Global Choroidal Neovascularization Drug Revenue Market Share, 2017-2028
    6.3 By Region - Global Choroidal Neovascularization Drug Sales & Forecasts
        6.3.1 By Region - Global Choroidal Neovascularization Drug Sales, 2017-2022
        6.3.2 By Region - Global Choroidal Neovascularization Drug Sales, 2023-2028
        6.3.3 By Region - Global Choroidal Neovascularization Drug Sales Market Share, 2017-2028
    6.4 North America
        6.4.1 By Country - North America Choroidal Neovascularization Drug Revenue, 2017-2028
        6.4.2 By Country - North America Choroidal Neovascularization Drug Sales, 2017-2028
        6.4.3 US Choroidal Neovascularization Drug Market Size, 2017-2028
        6.4.4 Canada Choroidal Neovascularization Drug Market Size, 2017-2028
        6.4.5 Mexico Choroidal Neovascularization Drug Market Size, 2017-2028
    6.5 Europe
        6.5.1 By Country - Europe Choroidal Neovascularization Drug Revenue, 2017-2028
        6.5.2 By Country - Europe Choroidal Neovascularization Drug Sales, 2017-2028
        6.5.3 Germany Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.4 France Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.5 U.K. Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.6 Italy Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.7 Russia Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.8 Nordic Countries Choroidal Neovascularization Drug Market Size, 2017-2028
        6.5.9 Benelux Choroidal Neovascularization Drug Market Size, 2017-2028
    6.6 Asia
        6.6.1 By Region - Asia Choroidal Neovascularization Drug Revenue, 2017-2028
        6.6.2 By Region - Asia Choroidal Neovascularization Drug Sales, 2017-2028
        6.6.3 China Choroidal Neovascularization Drug Market Size, 2017-2028
        6.6.4 Japan Choroidal Neovascularization Drug Market Size, 2017-2028
        6.6.5 South Korea Choroidal Neovascularization Drug Market Size, 2017-2028
        6.6.6 Southeast Asia Choroidal Neovascularization Drug Market Size, 2017-2028
        6.6.7 India Choroidal Neovascularization Drug Market Size, 2017-2028
    6.7 South America
        6.7.1 By Country - South America Choroidal Neovascularization Drug Revenue, 2017-2028
        6.7.2 By Country - South America Choroidal Neovascularization Drug Sales, 2017-2028
        6.7.3 Brazil Choroidal Neovascularization Drug Market Size, 2017-2028
        6.7.4 Argentina Choroidal Neovascularization Drug Market Size, 2017-2028
    6.8 Middle East & Africa
        6.8.1 By Country - Middle East & Africa Choroidal Neovascularization Drug Revenue, 2017-2028
        6.8.2 By Country - Middle East & Africa Choroidal Neovascularization Drug Sales, 2017-2028
        6.8.3 Turkey Choroidal Neovascularization Drug Market Size, 2017-2028
        6.8.4 Israel Choroidal Neovascularization Drug Market Size, 2017-2028
        6.8.5 Saudi Arabia Choroidal Neovascularization Drug Market Size, 2017-2028
        6.8.6 UAE Choroidal Neovascularization Drug Market Size, 2017-2028
7 Manufacturers & Brands Profiles
    7.1 Cellphire, Inc.
        7.1.1 Cellphire, Inc. Corporate Summary
        7.1.2 Cellphire, Inc. Business Overview
        7.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.1.5 Cellphire, Inc. Key News
    7.2 Chrysalis BioTherapeutics, Inc.
        7.2.1 Chrysalis BioTherapeutics, Inc. Corporate Summary
        7.2.2 Chrysalis BioTherapeutics, Inc. Business Overview
        7.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.2.5 Chrysalis BioTherapeutics, Inc. Key News
    7.3 Cleveland BioLabs, Inc.
        7.3.1 Cleveland BioLabs, Inc. Corporate Summary
        7.3.2 Cleveland BioLabs, Inc. Business Overview
        7.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.3.5 Cleveland BioLabs, Inc. Key News
    7.4 Cumberland Pharmaceuticals, Inc.
        7.4.1 Cumberland Pharmaceuticals, Inc. Corporate Summary
        7.4.2 Cumberland Pharmaceuticals, Inc. Business Overview
        7.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.4.5 Cumberland Pharmaceuticals, Inc. Key News
    7.5 Diffusion Pharmaceuticals Inc.
        7.5.1 Diffusion Pharmaceuticals Inc. Corporate Summary
        7.5.2 Diffusion Pharmaceuticals Inc. Business Overview
        7.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.5.5 Diffusion Pharmaceuticals Inc. Key News
    7.6 Eli Lilly and Company
        7.6.1 Eli Lilly and Company Corporate Summary
        7.6.2 Eli Lilly and Company Business Overview
        7.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Major Product Offerings
        7.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.6.5 Eli Lilly and Company Key News
    7.7 GNI Group Ltd.
        7.7.1 GNI Group Ltd. Corporate Summary
        7.7.2 GNI Group Ltd. Business Overview
        7.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Major Product Offerings
        7.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.7.5 GNI Group Ltd. Key News
    7.8 Humanetics Corporation
        7.8.1 Humanetics Corporation Corporate Summary
        7.8.2 Humanetics Corporation Business Overview
        7.8.3 Humanetics Corporation Choroidal Neovascularization Drug Major Product Offerings
        7.8.4 Humanetics Corporation Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.8.5 Humanetics Corporation Key News
    7.9 INSYS Therapeutics, Inc.
        7.9.1 INSYS Therapeutics, Inc. Corporate Summary
        7.9.2 INSYS Therapeutics, Inc. Business Overview
        7.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.9.5 INSYS Therapeutics, Inc. Key News
    7.10 Meabco A/S
        7.10.1 Meabco A/S Corporate Summary
        7.10.2 Meabco A/S Business Overview
        7.10.3 Meabco A/S Choroidal Neovascularization Drug Major Product Offerings
        7.10.4 Meabco A/S Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.10.5 Meabco A/S Key News
    7.11 Neumedicines Inc.
        7.11.1 Neumedicines Inc. Corporate Summary
        7.11.2 Neumedicines Inc. Choroidal Neovascularization Drug Business Overview
        7.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.11.5 Neumedicines Inc. Key News
    7.12 Onconova Therapeutics, Inc.
        7.12.1 Onconova Therapeutics, Inc. Corporate Summary
        7.12.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Business Overview
        7.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.12.5 Onconova Therapeutics, Inc. Key News
    7.13 PharmaIN Corporation
        7.13.1 PharmaIN Corporation Corporate Summary
        7.13.2 PharmaIN Corporation Choroidal Neovascularization Drug Business Overview
        7.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Major Product Offerings
        7.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.13.5 PharmaIN Corporation Key News
    7.14 Pluristem Therapeutics Inc.
        7.14.1 Pluristem Therapeutics Inc. Corporate Summary
        7.14.2 Pluristem Therapeutics Inc. Business Overview
        7.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.14.5 Pluristem Therapeutics Inc. Key News
    7.15 ProCertus BioPharm Inc.
        7.15.1 ProCertus BioPharm Inc. Corporate Summary
        7.15.2 ProCertus BioPharm Inc. Business Overview
        7.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.15.5 ProCertus BioPharm Inc. Key News
    7.16 RDD Pharma Ltd.
        7.16.1 RDD Pharma Ltd. Corporate Summary
        7.16.2 RDD Pharma Ltd. Business Overview
        7.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Major Product Offerings
        7.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.16.5 RDD Pharma Ltd. Key News
    7.17 RedHill Biopharma Ltd.
        7.17.1 RedHill Biopharma Ltd. Corporate Summary
        7.17.2 RedHill Biopharma Ltd. Business Overview
        7.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Major Product Offerings
        7.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.17.5 RedHill Biopharma Ltd. Key News
    7.18 RxBio, Inc.
        7.18.1 RxBio, Inc. Corporate Summary
        7.18.2 RxBio, Inc. Business Overview
        7.18.3 RxBio, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.18.4 RxBio, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.18.5 RxBio, Inc. Key News
    7.19 Soligenix, Inc.
        7.19.1 Soligenix, Inc. Corporate Summary
        7.19.2 Soligenix, Inc. Business Overview
        7.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Major Product Offerings
        7.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Sales and Revenue in Global (2017-2022)
        7.19.5 Soligenix, Inc. Key News
8 Global Choroidal Neovascularization Drug Production Capacity, Analysis
    8.1 Global Choroidal Neovascularization Drug Production Capacity, 2017-2028
    8.2 Choroidal Neovascularization Drug Production Capacity of Key Manufacturers in Global Market
    8.3 Global Choroidal Neovascularization Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
    9.1 Market Opportunities & Trends
    9.2 Market Drivers
    9.3 Market Restraints
10 Choroidal Neovascularization Drug Supply Chain Analysis
    10.1 Choroidal Neovascularization Drug Industry Value Chain
    10.2 Choroidal Neovascularization Drug Upstream Market
    10.3 Choroidal Neovascularization Drug Downstream and Clients
    10.4 Marketing Channels Analysis
        10.4.1 Marketing Channels
        10.4.2 Choroidal Neovascularization Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
    12.1 Note
    12.2 Examples of Clients
    12.3 Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com